In other words, Ozempic is a diabetes medication first, with cardiovascular and kidney protection built onto that indication
(Diabetes Obes Metab, 2017) showed that semaglutide at 1.0 mg reduced ad libitum energy intake by approximately 24% versus placebo
At therapeutic doses, GLP-1 medications can delay gastric emptying by roughly 3050% during the early phases of treatment , which contributes to reduced post-meal glucose spikes and improved satiety signaling
More recently, evik et al
GLOW is studied in preclinical research on tissue repair model systems, vascular endothelial signaling, fibroblast migration, and matrix metalloproteinase activity
Beust De Lima DDSA, Da Silva J